Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: A multicenter study
- 1 June 2021
- journal article
- research article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 84 (6) , 1554-1561
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
This publication has 37 references indexed in Scilit:
- Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic MelanomaJAMA Dermatology, 2015
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trialThe Lancet, 2015
- A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)Annals of Oncology, 2015
- Comparative profile of cutaneous adverse events: BRAF/MEK inhibitor combination therapy versus BRAF monotherapy in melanomaJournal of the American Academy of Dermatology, 2014
- Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b studyThe Lancet Oncology, 2014
- The clinical development of MEK inhibitorsNature Reviews Clinical Oncology, 2014
- Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label studyThe Lancet Oncology, 2014
- Analysis of Dermatologic Events in Vemurafenib-Treated Patients With MelanomaThe Oncologist, 2013
- Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic BRAF-Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF InhibitorJournal of Clinical Oncology, 2013
- BRIM-1, -2 and -3 Trials: Improved Survival with Vemurafenib in Metastatic Melanoma Patients with a BRAF V600E MutationFuture Oncology, 2012